Published Online:23 Dec 2010https://doi.org/10.4155/tde.10.83
Abstract
Attempts to deliver drugs into and through the skin (dermal and transdermal delivery) have not been very successful because the physicochemical properties of drugs are often not optimal. Prodrugs can be used to optimize those physicochemical properties of drugs and optimize their delivery by transiently masking their polar functional groups. For a drug to cross the rate-limiting barrier to delivery (the stratum corneum) it must dissolve in and cross multiple lipid and aqueous phases within the stratum corneum. Prodrugs can be designed to exhibit increased lipid and aqueous solubilities resulting in increased delivery. In order to identify the optimal prodrugs, they must be evaluated as saturated solutions where their thermodynamic activities are maximal in the solution and in the skin. If prodrugs are evaluated at concentrations less than at saturation, inaccurate conclusions about the optimal physicochemical properties may result. Prodrugs must be designed to optimize both their lipid and aqueous solubilities to optimize their delivery into and through the skin.
Papers of special note have been highlighted as: ▪ of interest
Bibliography
- 1 Prodrugs: Challenges and Rewards Part I and II. Stella VJ, Borchardt RT, Hageman MJ, Oliyai R, Maag H, Tilly JW. (Eds). Springer Science, NY, USA (2007).
- 2 Sloan KB. Functional group considerations in the development of prodrug approaches to solving topical delivery problems. In: Prodrugs: Topical and Ocular Drug Delivery. Sloan KB (Ed.). Marcel Dekker Inc, NY, USA, 17–116 (1992).
- 3 Morrison RT, Boyd RN. In: Organic Chemistry (6th Edition). Allyn and Bacon Inc, MA, USA (2003).
- 4 Bundgaard H, Rasmussen GJ. Prodrugs of peptides. 11. Chemical and enzymatic hydrolysis kinetics of N-acyloxymethyl derivatives of a peptide-like bond. Pharm. Res.8,1238–1242 (1991).
- 5 Sloan KB, Wasdo SC, Rautio J. Design for optimized topical delivery: prodrugs and a paradigm change. Pharm. Res.23,2729–2747 (2006).
- 6 Sloan KB, Wasdo SC. The role of prodrugs in penetration enhancement. In: Percutaneous Penetration Enhancers (2nd Edition). Smith EW, Maibach HI (Eds). Taylor and Francis, NY, USA, 51–64 (2006).
- 7 Kadir R, Stempler D, Liron Z, Cohen S. Delivery of theophylline into excised human skin from alkanoic acid solutions: a ‘pushûpull’ mechanism. J. Pharm. Sci.76,774–779 (1987).▪ Initial articulation of thermodynamic bases for two different mechanisms of topical penetration enhancement.
- 8 Sloan KB, Koch SAM, Siver KB. Mannich base derivatives of theophylline and 5-fluorouracil: syntheses, properties and topical delivery characteristics. Int. J. Pharm.21,251–264 (1984).▪ Initial articulation of the hypothesis that the dependence of skin permeation on the water as well as the lipid solubilities of the permeant derives from the solubilizing properties of the rate-limiting barrier to permeation.
- 9 Majumdar S, Thomas J, Wasdo S, Sloan KB. The effect of water solubility of solutes on their flux through human skin in vitro. Int. J. Pharm.329,25–36 (2007).▪ Initial report on the extension of Fick’s law to the delivery of molecules from a water vehicle through human skin showing that both lipid and aqueous solubilities of the permeant are important to optimize topical delivery.
- 10 Juntunen J, Majumdar S, Sloan KB. The effect of water solubility of solutes on their flux through human skin in vitro: a prodrug database integrated into the extended Flynn database. Int. J. Pharm.351,92–103 (2008).▪ Most recent report on the extension of Fick’s law to the delivery of molecules from a water vehicle through human skin showing that both lipid and aqueous solubilities are important to optimize topical delivery.
- 11 Roberts WJ, Sloan KB. Correlation of aqueous and lipid solubilities with flux for prodrugs of 5-fluorouracil, theophylline and 6-mercaptopurine: a Potts–Guy approach. J. Pharm. Sci.88,515–522 (1999).▪ Initial report on the extension of Fick’s law to the delivery of molecules from a lipid vehicle through hairless mouse skin showing that both the lipid and aqueous solubilities of the permeant are important to optimize topical delivery.
- 12 Higuchi T. Physical chemical analysis of percutaneous absorption process from creams and ointments. J. Soc. Cosmet. Chem.11,85–97 (1960).▪ Initial articulation of the importance of thermodynamic considerations in understanding skin permeation.
- 13 Zhang Q, Grice JE, Li P, Jepps OG, Wang G, Roberts MS. Skin solubility determines maximum transepidermal flux for similar size molecules. Pharm. Res.26,1974–1985 (2009).
- 14 Roberts WJ, Sloan KB. Prediction of transdermal flux of prodrugs of 5-fluorouracil, theophylline and 6-mercaptopurine with a series/parallel model. J. Pharm. Sci.89,1415–1431 (2000).
- 15 Beall HD, Sloan KB. Transdermal delivery of 5-fluorouracil (5-FU) by 1-alkylcarbonyl-5-FU prodrugs. Int. J. Pharm.129,203–210 (1996).
- 16 Michaels AS, Chandrasekaran SK, Shaw JE. Drug Permeation through human skin: theory and in vitro experimental measurement. AIChE J.21,985–996 (1975).▪ Initial articulation of the hypothesis that skin permeation takes place through a lipid matrix between skin cells (corneocytes): the ‘bricks and mortar model’.
- 17 Bouwstra JA, Gooris GS, Dubblelaar FER, Ponec M. The lipid organization in the skin barrier. Acta Derm. Venereol.208,23–30 (2000).▪ Initial articulation of the hypothesis that skin permeation takes place through a liquid lipid layer between two crystalline lipid layers in the lipid bilayers parallel to the orientation of the skin cells: the ‘sandwich model’.
- 18 Keesner D, Ruettinger A, Kiselev MA, Wartewig S, Neubert RHH. Properties of ceramides and their impact on the stratum corneum structure: a review. Skin Pharmacol Physiol.21,58–74 (2008).
- 19 Bouwstra JA, Gooris GS, van der Spek JA, Bras W. Structural investigation of human stratum corneum by small angle x-ray scattering. J. Invest. Dermatol.97,1005–1012 (1991).
- 20 Bouwstra JA, Gooris GS, Dubblelaar FER, Ponec M. Phase behavior of stratum corneum lipid mixtures based on human ceramides: the role of natural and synthetic ceramide 1. J. Invest. Dermatol.118,606–617 (2002).
- 21 Walkley K. Bound water in stratum corneum measured by differential scanning calorimetry. J. Invest. Dermatol.59,225–227 (1972).
- 22 Kiselev MA, Ryabova NY, Balagurov AM et el. New insights into the structure and hydration of a stratum corneum lipid model membrane by neutron diffraction. Eur. Biophys. J.34,1030–1040 (2005).
- 23 Lofgren H, Pascher I. Molecular arrangements of sphingolipids. The monolayer behavior of ceramides. Chem. Phys. Lipid.20,273–284 (1977).
- 24 Forslind B. A domain mosaic model of the skin barrier. Acta Derm. Venerol.74,1–6 (1994).▪ Initial articulation of the hypothesis that skin permeation takes place between domains of dissimilar lipids perpendicular to the orientation of the skin cells: the ‘domain mosaic model’.
- 25 Forslind B, Engstrom S, Engblom J, Norlen L. A novel approach to the understanding of human skin barrier function. J. Derm. Sci.14,115–125 (1997).
- 26 Sloan KB, Wasdo SC. Designing for topical delivery: prodrugs can make the difference. Med. Res. Rev.23,763–793 (2003).
- 27 Roberts WJ, Sloan KB. Topical delivery of 5-fluorouracil (5-FU) by 3-alkylcarbonyloxymethyl-5-FU prodrugs. J. Pharm. Sci.92,1028–1036 (2003).
- 28 Wasdo SC, Juntunen J, Devarajan H, Sloan KB. A comparison of the fit of flux through hairless mouse skin from water data to three model equations. Int. J. Pharm.366,65–73 (2009).▪ Most recent report of the extension of Fick’s law to the delivery of molecules from a water vehicle through hairless mouse skin showing that both lipid and aqueous solubilities are important to optimize topical delivery.
- 29 Thomas JD, Sloan KB. Evaluation of alkyloxycarbonyloxymethyl (AOCOM) ethers as novel prodrugs of phenols for topical delivery. Int. J. Pharm.371,25–32 (2009).▪ Most recent report on the extension of Fick’s law to the delivery of molecules from a lipid vehicle through hairless mouse skin showing that both lipid and aqueous solubilities are important to optimize topical delivery.
- 30 Waranis RP, Sloan KB. Effect of vehicular and prodrug properties and their interactions on the delivery of 6-mercaptopurine through skin: S6-acyloxymethyl-6-mercaptopurine prodrugs. J. Pharm. Sci.77,210–215 (1988).
- 31 Wasdo SC, Sloan KB. Topical delivery of a model phenolic prodrug: alkyloxycarbonyl prodrugs of acetaminophen. Pharm. Res.21,940–946 (2004).
- 32 Thomas JD, Sloan KB. In vitro evaluation of alkylcarbonyloxymethyl (ACOM) ethers as novel prodrugs of phenols for topical delivery: ACOM prodrugs of acetaminophen. Int. J. Pharm.346,80–88 (2007).
- 33 Majumdar S, Sloan KB. Synthesis and topical delivery of N-alkyl-N-alkyloxycarbonylaminomethyl prodrugs of a model phenolic drug: acetaminophen. Int. J. Pharm.337,48–55 (2007).
- 34 Stinchcomb AL, Swaan PW, Ekabo O et el. Straight chain naltrexone ester prodrugs: diffusion and concurrent esterase biotransformation in human skin. J. Pharm. Sci.91,2571–2578 (2002).
- 35 Pillai O, Hamad MO, Crooks PA, Stinchcomb AL. Physicochemical evaluation, in vitro human skin diffusion, and concurrent biotransformation of 3-O-alkyl carbonate prodrugs of naltrexone. Pharm. Res.21,1146–1152 (2004).
- 36 Vaddi HK, Hamad MO, Chen J, Banks SL, Crooks PA, Stinchcomb AL. Human skin permeation of branched chain 3-O-alkyl ester and carbonate prodrugs of naltrexone. Pharm. Res.22,758–765 (2005).
- 37 Vaddi HK, Banks SL, Chen J, Hammell DC, Crooks PA, Stinchcomb AL. Human skin permeation of 3-O-alkyl carbamate prodrugs of naltrexone. J. Pharm. Sci.98,2611–2625 (2009).
- 38 Kiptoo PK, Hamad MO, Crooks PA, Stinchcomb AL. Enhancement of transdermal delivery of 6-b-naltrexol via a co-drug linked to hydroxybupropion. J. Control. Release.113,137–145 (2006).
- 39 Kiptoo PK, Paudel KS, Hammell DC et el. Transdermal delivery of bupropion and its active metabolite, hydroxybupropion: a prodrug strategy as an alternative approach. J. Pharm. Sci.90,583–594 (2009).
- 40 Hammell DC, Hamad MO, Vaddi HK, Crooks PA, Stinchcomb AL. A duplex ‘gemini’ prodrug of naltrexone for transdermal delivery. J. Control. Release97,283–290 (2004).
